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Introduction: Aspirin hypersensitivity represents two distinct clinical syndromes, such as
aspirin exacerbated respiratory disease (AERD) and aspirin-intolerant chronic urticaria/angioe-
dema (AICU) which have different clinical phenotypes resulting from different genetic back-
grounds in a Korean population. Persistent eosinophilic inflammation in airway is
a characteristic feature of AERD and chemokine CC motif receptor 3 (CCR3) plays an important
role in eosinophilic infiltration into the asthmatic airway.
Objectives: The main objective of this study is to investigate the association between CCR3
gene polymorphisms and aspirin hypersensitivity, including AERD and AICU.
Methods: CCR3 mRNA expression was measured after an aspirin provocation test by real-time
PCR. In total, 330 patients with aspirin hypersensitivity (191 AERD and 139 AICU) and 217
normal healthy controls (NC) were genotyped for two CCR3 promoter polymorphisms (-520T/
G and -174C/T), and the functional effects of the polymorphisms were analyzed applying
a luciferase reporter assay and an electrophoretic mobility shift assay.
Results: CCR3 mRNA expression was significantly increased after aspirin provocation in AERD
patients (PZ 0.002) but not in AICU patients. An in vitro functional study showed that the
reporter constructhavinga -520Galleleexhibited significantlyhigherpromoteractivity compared
with the construct having a -520T allele in human myeloid (U937), lymphoid (Jurkat), and mast
(HMC-1) cell lines (P< 0.001). We found -520G and -174T specific bands on EMSA.
Conclusion: This result suggests that the CCR3 genetic polymorphisms may contribute to the
development of the AERD phenotype and may be used as a genetic marker for differentiating
between the two major aspirin hypersensitivity phenotypes.
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1 219 5196; fax: þ82 31 219 5154.
(H.-S. Park).
9 Elsevier Ltd. All rights reserved.
CCR3 gene polymorphism with AERD 627Introduction
A hypersensitivity to aspirin or other nonsteroidal anti-
inflammatory drugs (NSAIDs) results in two distinct clinical
syndromes, such as aspirin exacerbated respiratory disease
(AERD) and aspirin-intolerant chronic urticaria/angioedema
(AICU).1e3
In a Korean population, ingestion of aspirin or NSAIDs
has been found to exacerbate asthmatic symptoms in
about 20% of adult asthmatics4 and to worsen cutaneous
symptom, such as wheal and swelling, in more than 30% of
chronic urticaria patients.5 Aspirin hypersensitivity may
result from the inhibitory action of aspirin on the forma-
tion of prostaglandin, but the pathogenic mechanisms and
genetic backgrounds of two clinical syndromes, AERD and
AICU, may be different. In the Korean population, the
majority of AERD patients demonstrated a non-allergic and
non-IgE-mediated phenotype, while AICU patients showed
higher atopic rates and higher total serum IgE levels than
aspirin-tolerant chronic urticaria patients.5 We have also
reported the differing genetic backgrounds for AERD and
AICU; cysteinyl leukotriene receptor type 1 (CysLTR1)
genetic polymorphisms are associated with AERD but not
with AICU,6,7 while high-affinity IgE receptor alpha
(FCER1A) genetic polymorphisms are associated with
AICU.8 These findings indicate that these two distinct
syndromes of aspirin hypersensitivity have different clin-
ical phenotypes resulting from different genetic back-
grounds. Therefore, the aim of this study was to find
a genetic marker that differentiates between AERD and
AICU, so that it could be used as a genetic marker for
diagnosing these two major aspirin hypersensitivity
phenotypes.
The CCR3 gene encodes a G protein-coupled receptor
that responds to a variety of CC chemokines, including
eotaxin (CCL11), eotaxin-3 (CCL26), MCP-3 (CCL7), MCP-4
(CCL13), and RANTES (CCL5).9,10 It expressed not only in
eosinophils but also in basophils, Th2 lymphocytes,
macrophages, and airway epithelial cells.9e12 Its impor-
tance in airway eosinophilic inflammation has been
addressed in several studies.12e14 CCR3 is critical for
eosinophilic infiltration into airways,12,13 and CCR3 antag-
onists are likely to be effective therapies for asthma.14
Aspirin hypersensitivity and the aspirin triad are
usually accompanied by eosinophilia of the upper and
lower airways.15 Eosinophilic infiltration in bronchial or
nasal polyps is a characteristic feature of AERD.16,17 In
aspirin-sensitive polyps the number of eosinophils is
significantly increased and eotaxin levels are also higher
than in non-allergic or allergic patients.18 Considering the
pronounced eosinophilic infiltration in AERD patients, we
hypothesized that airway eosinophilic inflammation via
dysregulation of the CCR3 gene may play an important
role in AERD.
In this study, we examined CCR3 gene expression in
peripheral blood mononuclear cells from patients with
aspirin hypersensitivity after an aspirin challenge test, and
then investigated whether the CCR3 gene polymorphism is
associated with the differentiation of aspirin hypersensi-
tivity by conducting a genetic caseecontrol study among
Korean subjects.Materials and methods
Study subjects of genetic association study
Three hundred and thirty patients with aspirin hypersensi-
tivity which consist of 191 AERD patients and 139 AICU
patients, and 217 normal healthy volunteers were enrolled
at Ajou University Hospital, Suwon, Korea. The AICU
patients were defined as those who had had more than 6
weeks of daily itchy wheals; had a history of chronic urti-
caria/angioedema, which was aggravated by ingestion of
more than two kinds of NSAIDs; and showed positive
responses to the oral aspirin challenge test. The AERD
patients were chronic asthmatic patients showing a positive
response to a lysine aspirin bronchoprovocation test. The
AERD patients had upper and lower respiratory symptoms
without any history of drug-induced cutaneous symptoms.
Patients who had both AERD and AICU were excluded for
the study. All subjects gave informed consent, and the
protocol was approved by the institutional review board of
Ajou University Hospital, Korea.
Genomic DNA preparation and SNP genotyping
Genomic DNA was prepared from peripheral blood samples
using the Puregene DNA purification kit (Gentra, Minneap-
olis, MN, USA) according to the manufacturer’s protocol.
Genotyping was performed using the SNaPSHOT ddNTP
primer extension kit (Applied Biosystems, Foster City, CA,
USA). The sequences of the amplifying and extension
primers for CCR3-520T/G were as follows: forward, 50-AGC
CAGGTTCCTCAAGTC-30; reverse, 50-TCTCTTACGGCATTTTG
C-30; and extension, 50-TTTCCCCATTAACTATAATGAATG-30.
The sequences of the amplifying and extension primers for
CCR3-174C/T were: forward, 50-AATGCAAAATGCCGTAAG-30;
reverse, 50-ACAAACTGGGCCATCAG-30; and extension, 50-GG
CATATCAGAGGTGCCAGGA-30.
Changes of mRNA expression from peripheral blood
mononuclear cells during the aspirin challenge test
For this study, we enrolled 15 AERD, 23 AICU and 26 normal
volunteers among the study subjects enrolled for the
genetic association study. We matched age and gender
distribution, and gave them an aspirin challenge test. All
subjects gave informed consent, and the protocol was
approved by the institutional review board of Ajou
University Hospital, Korea. All medications, including
theophyllines, b2 agonists, leukotriene receptor antago-
nist, anti-histamines, and inhaled corticosteroids were
stopped 3 days before the aspirin provocation procedure.7
The AERD patients were challenged with lysine aspirin
inhalations and the AICU patients were challenged via oral
routes as described previously.6e8 At first, a placebo chal-
lenge was performed for AERD patients followed by a lysine
aspirin (L-ASA) bronchoprovocation test with increasing
doses of aspirin (75e300 mg/ml Althargyl; Dong A Pharma-
ceutical Co., Ltd., Korea) with monitoring of lung function
for more than 5 h. A percent change of FEV1 within 5 h
without any cutaneous symptoms was considered a positive
628 S.-H. Kim et al.result for the AERD patients. The changes of FEV1 in 1 s
were monitored following the final dose of the aspirin
challenge. The ASA induced change in FEV1 was calculated
as the percentage of post-challenge FEV1 relative to pre-
challenge FEV1 and was defined as positive if the FEV1 level
declined more than 20% from the baseline.
For normal healthy controls and the AICU patients,
500 mg of aspirin (Rhonal; KunWha Pharmaceutical Co.,
Seoul, Korea) in tablet form was administered orally, and
the subjects were observed for 4 h with monitoring for
urticaria and change in lung functions every 30 min. The
appearance within 4 h of urticaria without any changes in
FEV1 was considered a positive result for the AICU patients,
and no change in FEV1 within 7 h and any cutaneous
symptoms were considered as normal healthy controls.
Real-time PCR
Peripheral blood samples (10 ml) were collected from the
study subjects at two points, before the provocation test and
at the appearance of the disease symptoms (respiratory
symptoms forAERDandcutaneous symptomforAICUpatients)
after the provocation using FicollePaque Plus (Amersham
Biosciences, Sweden) density gradient centrifugation. For
normal healthy controls, samples were collected before the
oral provocation test and at 6 h later. Total RNAwas extracted
from peripheral blood mononuclear cells using the TRI
Reagent (MRC, USA). Real-time PCR was performed for
examination of CCR3 mRNA expression using the ABI Prism
7500 instrument. The PCR consisted of the cDNA product
(200 ng), 125 nM of primer, and 12.5 ml of 2 SYBR Green PCR
MasterMix (SYBRGreen dye, AmpliTaqGold, DNApolymerase,
dNTP mix, and optimized buffer components; Applied Bio-
systems) in a total volume of 20 ml. The following primer pairs
were used: for CCR3, forward 50-CATTTCGGACCTGCTCTTCC-
30, and reverse, 50-TGA CAGTCCGGGCTCGAAGG-30; and for b-
actin, forward, 50-TCCTTCTGCATCCTGTCGGC-30, and
reverse, 50-CAAGAGATGGCCACGGCTGC-30. Amplification was
performed for 40 cycles. Following an initial hot start for
10 min, each cycle consisted of 10 s of denaturation, 30 s of
annealing at 60 C, and 33 s of extension. RelativeCCR3mRNA
expression was calculated using the 2DDCT method,19 where
DDCTZ (CT, CCR3 gene CT, ACTB gene)sample (CT, CCR3
gene CT, ACTB gene)standard.
In vitro promoter activity assay
A 587 bp fragment (from558 toþ29) having the human CCR3
genetic polymorphisms was amplified by polymerase chain
reaction (PCR) using the following primers: forward 50-TC
TTCAAGGTTCAATTTCCCC-30, and reverse 50-GTCTCAACTGTAT
CTAGTGAGG-30. Following digestion with Kpn1 and Xho1
(Takara, Shiga, Japan), the fragment was ligated into a Kpn1/
Xho1-digested pGL3 basic vector (Promega,Madison,WI, USA).
The haplotype 1[TC], 2[GT] and 3[GC] fragments were ampli-
fied from the DNA of -520 and -174 homozygous and heterozy-
gous subjects. Thehaplotype4[TT] constructwas generatedby
site-directedmutagenesis using the haplotype 1[TC] luciferase
reporter construct as template. Site-directedmutagenesiswas
performed using the overlap extension PCR mutagenesis
technique with the following primers: Set 1, forward 50-TCTTC
AAGGTTCAATTTCCCC-30, and reverse: 50-GGTGCCAGGAAAGGATTGA-30; Set 2, forward: 50-TCAATCCTTTTCCTGGCACC-30,
and reverse: 50-GTCTCAACTGTATCTAGTGAGG-30. Prior to
transfection, the plasmids were sequenced by the dideoxy
chain terminator method and analyzed on an ABI 310DNA
sequencer (Applied Biosystems).
Four luciferase reporter constructs for the common and
rare genotypes were transiently transfected into a myelo-
monocytic cell line (U937) with lipofectamin (Invitrogen, CA,
USA). Other cell lines, consisting of human monocyte cells
(THP-1) and human mast cells (HMC-1), were transfected by
an electroporator. Briefly, 2 105 cells were seeded in 12-
well plates and transfected with 1 mg of the reporter
construct and 5 ng of PRL SV40 renilla control vector using
lipofectamin (ratio, 1:5). The THP-1 and HMC-1 cells were
seeded in 24-well plates and transfected using a micro-
porator (Incyto, Suwon, Korea). At 24e48 h post-trans-
fection, the cells were lysed and assayed for firefly luciferase
activity according to the manufacturer’s instructions
(Promega, Madison, WI, USA). The transfections and lucif-
erase assays were repeated four times in triplicate (nZ 12).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay was performed
according to the method described previously using nuclear
extracts from U937 cells.7 The following double-stranded
oligonucleotides were used as probes for the electropho-
retic mobility shift assay (EMSA): for CCR3 -520T/G, 50-AT
AATGAATG [T/G] CTCATCATTA-30; for CCR3 -174A/C, 50-CT
CAATCCTT [C/T] TCCTGGCAC’-3; and for OCT1 as
a nonspecific competitor, 50- TGTCGAATGCAAATCACTAGA-
30. The double-stranded oligonucleotides were annealed by
incubation at 95 C for 5 min, followed by gradual cooling to
room temperature. The double-stranded DNA probes were
radiolabeled at their 50-ends with DNA polymerase I
(Klenow fragment) (Promega, Madison,WI, USA) and
[a-32P]CTP. The reaction mixtures (10 ml), which contained
5 mg of nuclear extract, 10 mM HEPES (pH 7.9), 200 ng of
poly(dI:dC), 0.005 mM MgCl2, 70 mM NaCl, 5 mM DTT, 1 mM
NaVO3, 10 mM NaF, 1 mM EDTA, and 5% glycerol, were
preincubated on ice for 20 min and then incubated for
20 min on ice in the presence of 0.2 pmol of radiolabeled
probe. The reaction mixtures were then subjected to
electrophoresis on a native 6% polyacrylamide gel. For
competition experiments, unlabeled blunt-ended compet-
itor oligonucleotides were added to the binding reaction
mixtures before the addition of the radiolabeled oligonu-
cleotide probes. The gels were dried, and radioactivity was
detected using a FLA7000 scanner (Fuji Photo Film, Tokyo,
Japan).
Data analysis
We employed a widely used measure of linkage disequilib-
rium between all pairs of biallelic loci, Lewontin’s D0(jD0j)
and r2. The haplotypes of the individuals were inferred
using the Expectation-Maximization Algorithm. The genetic
effects of the inferred haplotypes were analyzed in the
same way as the SNPs. We assessed the differences in
genotype frequency between the case and control groups
with a chi-square test and by calculating odds ratio (OR)
with 95% confidence intervals (CI). The distributions of
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logistic regression models that controlled for sex and age as
covariables with three alternative models (co-dominant,
dominant, and recessive models). We studied the differ-
ences in clinical characteristics between the groups with
the Student’s t test (for continuous variables) or a chi-
square test (for categorical variables). Differences in the
mRNA levels of the target genes were assessed with the
ManneWhitney test. A P value of less than 0.05 denoted
a statistically significant difference. The statistical analyses
were completed using SPSS version 12 software (SPSS Inc.,
Chicago, IL, USA).
Results
Caseecontrol association study of CCR3 gene
polymorphisms with aspirin hypersensitivity
To identify whether CCR3 gene polymorphisms may offer
a differential genetic marker between AERD and AICU, we
performed a genetic association study of the two poly-
morphisms of the CCR3 gene (-520T/G and -174C/T) in 330
patients with aspirin hypersensitivity and 217 normal
healthy controls. The clinical characteristics of the study
subjects are summarized in Table 1. AERD was more
commonly found in middle-aged females. The AICU patients
showed a higher rate of atopy than did the AERD patients
(P< 0.001).
In the genetic association analysis among patients with
aspirin hypersensitivity, two polymorphisms, -520T/G and
-174C/T, were found to be significantly associated with the
risk of AERD (Table 2); the frequency of the rare genotype
was significantly higher in AERD group than in the AICU
group (PZ 0.015, ORZ 2.003 for -520T/G, PZ 0.011,
ORZ 2.378 for -174C/T in a recessive analysis model). The
significance of each polymorphism remained after Bonfer-
roni’s correction (PZ 0.030 for -520T/G, PZ 0.022 for
-174C/T). The genotype frequency of the synonymous SNP,
51T/C, did not differ between the AERD and AICU groups. In
the genetic association analysis between group of patients
with aspirin hypersensitivity and the normal healthy control
group, no significant association was observed (data not
shown). There were no significant differences in mean age,
gender distribution, prevalence of atopy, or total IgE level
for the CCR3 genetic polymorphism (data not shown).Table 1 Clinical characteristics of the study subjects for casee
ASA (NZ 330) NC (NZ 217)
Sex (male/total) 138/330(41.8%) 96/217(44.2%)






5.11 1.21/282 3.63 1.34/49
ASA; patients with aspirin hypersensitivity, NC; normal healthy contr
intolerant chronic urticaria, N; number of patients.
a This value was presented as mean SD.The two polymorphisms of the CCR3 gene, -520T/G and
-174C/T, were strongly linked with each other (lD’lZ 1,
r2Z 0.778), so the haplotype analysis in association with
AERD was consistent with the genotype association result
(data not shown).
Differential expression of CCR3 gene after aspirin
challenge test in patients with AERD
To investigate how the CCR3 gene responds when asthmatic
symptoms are exacerbated by aspirin, we used quantitative
real-time PCR to measure mRNA expression in peripheral
blood mononuclear cells from patients with aspirin hyper-
sensitivity (AERD and AICU) and normal healthy controls.
We matched age and gender distribution among all volun-
teers who were given the aspirin challenge test. In AERD
patients the CCR3 mRNA expression significantly increased
following the aspirin challenge, together with an exacer-
bation of asthmatic symptoms (PZ 0.002), while no
significant changes were noted in normal healthy controls
and AICU patients (P> 0.05) (Fig. 1).
The functional effect of the CCR3 gene
polymorphism on transcriptional activity
To evaluate whether the CCR3 gene polymorphism was
associated with altered transcriptional activity, we used
luciferase reporter constructs having four different geno-
types (TC, GT, GC, TT) for the two polymorphisms, -520T/G
and-174C/T, of the CCR3 gene.
The constructs with the GC genotype exhibited signifi-
cantly greater luciferase activity compared with the other
constructs in the three different types of cells, human
myelomonocytic cells (U937, Fig. 2A), human mast cells
(HMC-1, Fig. 2B), and human T lymphocyte cells (Jurkat,
Fig. 2C) (all P< 0.001).
To investigate whether the CCR3 gene polymorphism
created a transcription factor binding site, we performed
an electrophoretic mobility shift assay (EMSA) with nuclear
extracts from U937 and THP-1 cells using double-stranded
oligonucleotide probes that corresponded to -520T/G and
-174C/T (Fig. 3). Specific bands were observed with the
-520T/G probe and the -174C/T probe (Fig. 3B and C). The
shifted band produced by the -520G probe completely
disappeared in the presence of the unlabeled -520G probe,control association study.







0.597 69/191(36.13%) 69/139(49.64%) 0.018
<0.001 43.28 13.47 35.24 11.59 <0.001
<0.001 93/178(52.25%) 101/138(73.19%) <0.001
<0.001 5.06 1.3 5.19 1.08 0.371
ol. AERD; aspirin exacerbated respiratory disease, AICU; aspirin-
Table 2 Allele and genotype frequencies of CCR3 gene polymorphisms.







-520T/G TT 131(39.7%) 79(36.4%) 0.391 72 (37.7%) 59(42.4%) 0.093
GT 150(45.5%) 103(47.5%) 0.647 84(44%) 66(47.5%) 0.547
GG 49(14.8%) 35(16.1%) 0.372 35(18.3%) 14(10.1%) 0.015
q 0.376 0.399 0.384 0.403 0.338 0.088
-174C/T CC 152(46.1%) 99(45.6%) 0.612 88(46.10%) 64(46.00%) 0.321
CT 142(43.0%) 92(42.4%) 0.605 76(39.80%) 66(47.50%) 0.765
TT 36(10.9%) 26(12.0%) 0.720 27(14.10%) 9(6.50%) 0.011
q 0.324 0.332 0.606 0.34 0.302 0.317
ASA; patients with aspirin hypersensitivity, AERD; aspirin exacerbated respiratory disease, AICU; aspirin-intolerant chronic urticaria,
N; number of patients, q; minor allele frequency. Each P value was calculated with co-dominant, dominant, and recessive models.
Logistic regression analysis was applied to control for age and sex as covariables. Bold character indicates significance.
630 S.-H. Kim et al.but it remained visible in the presence of the unlabeled
-520T probe (Fig. 3B). The shifted band produced by the
-174T probe was not visible in the presence of the unla-
beled -174T probe, but it remained visible in the presence
of the unlabeled -174G probe (Fig. 3C).
Discussion
Although it is generally accepted that an altered eicosanoid
metabolism is a factor in both asthma and urticaria,20 the
differences in clinical demographics between AERD and
AICU patients in the Korean population5,6 suggested that
different pathogenic mechanisms and genetic backgrounds
may be involved. Persistent upper and lower eosinophilic
inflammation with chronic rhinosinusitis and nasal polyposis
may be a prominent feature of AERD, while mast cell
activation through unknown mechanism may be important
in the pathogenesis of AICU.5e8
Considering the biological role of CCR3 in eosinophil
infiltration to both the skin and the lung,12,13 we first
investigated the role of CCR3 in aspirin hypersensitivity
using an aspirin challenge test and a caseecontrol associ-
ation study in Korean patients with aspirin hypersensitivity.
This study demonstrates a significant contribution of
CCR3 gene polymorphisms in AERD patients. In this study,
mRNA expression of CCR3 gene was detectable in periph-
eral blood mononuclear cells from each subject, and thereFigure 1 Changes of mRNA expression level of CCR3 gene after a
respiratory disease (AERD), (B) aspirin-intolerant urticaria/angioe
analysis was done by the Wilcoxon’s signed-ranks test.was a significant increase in the expression after exacer-
bation of asthmatic symptoms by an aspirin challenge in
AERD patients, but not in normal healthy controls and AICU
patients. However, we could not compare the protein
expression of CCR3 during aspirin challenges in two study
groups, AERD and AICU. This finding suggests that CCR3 may
play a role in the exaggeration of asthmatic symptoms
induced by aspirin exposure in AERD patients. However, an
exacerbation of cutaneous symptoms by aspirin exposure in
AICU patients may not be related to increased expression of
CCR3, because no significant changes were noted after
aspirin challenges.
In this study, we noted a significant association
between the CCR3 gene polymorphisms (-520T/G and
-174C/T) and AERD, with supporting evidence from in vitro
functional studies. Previously, genetic association studies
of CCR3 gene polymorphisms have been investigated on
asthmatics in different ethnic groups.21e24 Most of the
genetic studies were focused on two synonymous SNPs
(51T/C and 240C/T) and two non-synonymous SNPs (824 G/
A and 1052T/C). Genetic association results might be
controversial because of the ethnic differences. A silent
mutation T51C in the CCR3 gene was only associated with
asthma in a British population23 and not in Japanese,23
Taiwanese,22 and Korean populations.21 In addition, three
SNPs (240C/T, 824 G/A, and 1052T/C) were not poly-
morphic, and the synonymous SNP (51T/C) showed veryspirin challenges in three study groups, (A) aspirin exacerbated
dema (AICU) and (C) normal healthy control (NC). Statistical
Figure 2 Effect of two promoter polymorphisms of -520T/G, and -174C/T on the transcription activity of human CCR3 gene in
various cell lines, (A) human myeloid (U937), (B) lymphoid (Jurkat), and (C) mast (HMC-1) cell lines. The reporter gene constructs
contained the CCR3 polymorphisms, ht1[TC], ht2[GT], ht3[GC], and ht4[TT]. The relative luciferase activity (RLU) is represented as
the ratio of the activity to the luciferase activity in the cells transfected with the promoter-less basic vector, pGL3B. Data are the
mean values of four independent experiments (in total, triplicated for each sample, nZ 12), plus or minus the SD. Statistical
analysis was done by the ManneWhitney U-test.
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Instead, three intronic SNPs (-22557G/A, -520T/G, -174C/
T) were identified in a Korean population.21 In this study,
we targeted two intronic SNPs (-520T/G and -174C/T)
because these two SNPs are located 520 and 174 bp
upstream of the translation start site. Modulation of gene
expression by intronic sequences has been reported. We
previously reported that intronic sequences might consti-
tute a proximal promoter element located upstream of the
translation start site.8 According to our preliminary study,
the other intronic SNP (-22557G/A) of the CCR3 gene did
not show an association with aspirin hypersensitivity, so it
was excluded from further study.Figure 3 Electrophoretic mobility shift assay for the CCR3 gen
Nucleotide sequences of oligonucleotides used as probes and comp
alleles. Arrow represents -520G specific band. (C) Differential bind
arrow represent -174T specific band. Differential binding of a nucle
competition test was shown in lanes 3e15 using self, non-self, andThe two intronic SNPs, -520T/G and -174C/T, of the
CCR3 gene were significantly associated with AERD among
patients with aspirin hypersensitivity. The percentage of
patients having -520 G or -174T homozygous genotypes was
significantly higher in the AERD group than in the AICU
group. An in vitro functional study using a luciferase
reporter assay found that the -520G genotype exhibited
significantly higher promoter activity than the -520T geno-
type in three different human cell lines. However, lucif-
erase reporter constructs carrying -174C/T polymorphism
did not show any functional influence on the transcriptional
activity. We also found -520G specific DNA-binding protein
in EMSA, although we will need further investigation toe polymorphism using nuclear extracts from U937 cells. (A)
etitors. (B) Differential binding of a nuclear protein to -520T/G
ing of a nuclear protein to -174C/T alleles. Line arrow and dot
ar protein was represented by lane 1e2 according to SNPs. The
nonspecific probes.
632 S.-H. Kim et al.identify the transcription factor. In vitro functional study
demonstrated that the intronic SNP, -520T/G, of the CCR3
gene was capable of causing an increased transcription
level of the CCR3 gene.
Previously, it had been reported that eotaxin mRNA and
protein expressions were significantly increased in AERD16
and the eosinophilic nasal polyps might be a source of
eotaxin.18 Additionally, CCR3 mRNA and protein expressions
were increased in the bronchial mucosa of asthmatic
patients and related to airway hyperresponsiveness.14 In
this study, although the basal level of CCR3 mRNA expres-
sion were not significantly different between AICU and
AERD patients, it increased significantly after aspirin chal-
lenges with asthma symptom exacerbations, in the AERD
patients, not in AICU patients. Activation of eosinophils is
a characteristic finding of nasal and bronchial mucosa of
AERD.1,16 Taken together, we suggest that the increased
expression of CCR3 may be responsible for eosniophilic
inflammation in AERD patients. Furthermore, genetic
polymorphism of CCR3 severely increased eosinophilic
inflammation.
In conclusion, these findings suggest that the CCR3 gene
polymorphisms (-520T/G and -174C/T) could increase the
genetic susceptibility for AERD, which distinguishes
between lung and skin manifestation of aspirin hypersen-
sitivity, AERD and AICU. The CCR3-520T/G polymorphism
may exaggerate asthmatic symptoms after aspirin/NSAID
exposure by increasing the expression level of CCR3 in the
asthmatic airways of AERD patients, which suggests that
CCR3 antagonism might be useful in the management of
AERD. However, the exacerbation of cutaneous symptoms
by aspirin exposure in AICU patients may not be related to
increased expression of CCR3.Acknowledgments
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